C1CO34 Stock Overview
Cencora, Inc. sources and distributes pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cencora, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$575.82 |
| 52 Week High | US$629.00 |
| 52 Week Low | US$422.10 |
| Beta | 0.47 |
| 1 Month Change | -5.31% |
| 3 Month Change | -1.31% |
| 1 Year Change | 38.91% |
| 3 Year Change | 85.27% |
| 5 Year Change | n/a |
| Change since IPO | 211.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| C1CO34 | BR Healthcare | BR Market | |
|---|---|---|---|
| 7D | 0% | 6.9% | -1.1% |
| 1Y | 38.9% | 2.6% | 10.3% |
Return vs Industry: C1CO34 exceeded the BR Healthcare industry which returned 2.6% over the past year.
Return vs Market: C1CO34 exceeded the BR Market which returned 10.3% over the past year.
Price Volatility
| C1CO34 volatility | |
|---|---|
| C1CO34 Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in BR Market | 9.0% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: C1CO34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine C1CO34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 44,000 | Steve Collis | www.cencora.com |
Cencora, Inc. sources and distributes pharmaceutical products. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Cencora, Inc. Fundamentals Summary
| C1CO34 fundamental statistics | |
|---|---|
| Market cap | R$231.04b |
| Earnings (TTM) | R$9.55b |
| Revenue (TTM) | R$1.43t |
24.2x
P/E Ratio0.2x
P/S RatioIs C1CO34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C1CO34 income statement (TTM) | |
|---|---|
| Revenue | US$276.54b |
| Cost of Revenue | US$267.14b |
| Gross Profit | US$9.40b |
| Other Expenses | US$7.55b |
| Earnings | US$1.85b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.29 |
| Gross Margin | 3.40% |
| Net Profit Margin | 0.67% |
| Debt/Equity Ratio | 427.8% |
How did C1CO34 perform over the long term?
See historical performance and comparison